Table 1.
Baseline demographics in all patients and in the different therapy groups*.
| All patients | R0–1 resection | R2-resection and/or LAT | Systemic therapy alone | Best supportive care | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Age | <70 | 715 | 66% | 239 | 73% | 51 | 70% | 418 | 63% | 7 | 30% |
| ≥70 | 371 | 34% | 87 | 27% | 22 | 30% | 246 | 37% | 16 | 70% | |
| ECOG | PS 0 | 295 | 27% | 140 | 43% | 19 | 26% | 136 | 21% | 0 | 0% |
| PS 1–3 | 791 | 73% | 186 | 57% | 54 | 74% | 528 | 80% | 23 | 100% | |
| Primary tumor location | Right colon | 310 | 29% | 73 | 22% | 13 | 18% | 214 | 33% | 10 | 44% |
| Left colon | 396 | 37% | 142 | 44% | 34 | 47% | 218 | 33% | 2 | 9% | |
| Rectum | 374 | 35% | 111 | 34% | 26 | 36% | 226 | 34% | 11 | 48% | |
| Primary tumor resection | Operated upfront | 726 | 67% | 274 | 84% | 50 | 69% | 396 | 60% | 6 | 26% |
| Not operated | 360 | 33% | 52 | 16% | 23 | 32% | 268 | 40% | 17 | 74% | |
| Prior adjuvant chemotherapy | No | 748 | 69% | 178 | 55% | 46 | 63% | 503 | 76% | 21 | 91% |
| Adjuvant chemotherapy | 338 | 31% | 148 | 45% | 27 | 37% | 161 | 24% | 2 | 9% | |
| Number of metastatic sites | 1 | 586 | 54% | 278 | 85% | 31 | 43% | 267 | 40% | 10 | 44% |
| 2 to 6 | 500 | 46% | 48 | 15% | 42 | 58% | 397 | 60% | 13 | 57% | |
| Liver only metastases | Yes | 430 | 40% | 236 | 72% | 26 | 36% | 161 | 24% | 7 | 30% |
| No | 656 | 60% | 90 | 28% | 47 | 64% | 503 | 76% | 16 | 70% | |
| Liver involvement | <25% | 265 | 24% | 156 | 48% | 23 | 32% | 82 | 12% | 4 | 17% |
| ≥25% | 547 | 50% | 106 | 33% | 33 | 45% | 392 | 59% | 16 | 70% | |
| No liver metastases | 274 | 25% | 64 | 20% | 17 | 23% | 190 | 29% | 3 | 13% | |
| Presentation | Synchronous | 736 | 68% | 186 | 57% | 45 | 62% | 484 | 73% | 21 | 91% |
| Metachronous | 350 | 32% | 140 | 43% | 28 | 38% | 180 | 27% | 2 | 9% | |
| RAS status¶ | KRAS/NRAS wildtype | 520 | 49% | 165 | 52% | 25 | 35% | 317 | 49% | 13 | 65% |
| KRAS/NRAS mutant | 540 | 51% | 151 | 48% | 46 | 65% | 336 | 52% | 7 | 35% | |
| BRAF status¶ | BRAF wildtype | 539 | 85% | 188 | 94% | 34 | 92% | 310 | 81% | 7 | 58% |
| BRAF mutant | 93 | 15% | 12 | 6% | 3 | 8% | 73 | 19% | 5 | 42% | |
| Mismatch repair status¶ | pMMR | 302 | 95% | 102 | 94% | 19 | 100% | 178 | 96% | 3 | 75% |
| dMMR | 15 | 5% | 7 | 6% | 0 | 0% | 7 | 4% | 1 | 25% | |
| Not tested | 769 | ·· | 217 | ·· | 54 | ·· | 479 | ·· | 19 | ·· | |
⁎
Patients were divided into four groups: curative resection (R0–1), R2 resection of metastases or primary, Local Ablative Therapy (LAT) or not all tumor sites resected curatively (R2/LAT); systemic therapy only or best supportive care only (BSC) group.
¶
Proportions of total number of tested for RAS, BRAF, and MMR status
dMMR = deficient mismatch repair, ECOG = Eastern Cooperative Oncology Group; pMMR = proficient mismatch repair; PS = performance status.